CELC — Celcuity Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1603454 ·
Last close
$67.87
Market Cap
$3.32B
52W High
$151.02
52W Low
$45.03
ADV30
1,119,516
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -66,118,000 | -78,864,000 | 828,220,000 | 182,049,000 | 841,001,000 |
| Mar 2026 | 0 | — | -50,507,000 | -52,841,000 | 410,164,000 | 145,191,000 | 356,639,000 |
| Dec 2025 | 0 | — | -49,201,000 | -50,973,000 | 466,558,000 | 165,703,000 | 366,003,000 |
| Sep 2025 | 0 | — | -42,849,000 | -43,804,000 | 476,004,000 | 74,252,000 | 359,041,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-172,492,000
Investing CF
$-53,827,000
Financing CF
$355,032,000
CapEx
$-474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.90
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-501,738,000
Inventory
—
Receivables
$1,600,621
ST Investments
$241,873,000
EBIT TTM
$-172,836,000
Pretax Income TTM
$-192,886,000
Interest Exp TTM
$20,050,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,192,000 | -177,042,000 | 466,558,000 | 366,003,000 | 100,555,000 | -153,280,000 |
| Dec 2024 | 0 | -113,267,000 | -111,779,000 | 245,123,000 | 129,504,000 | 115,619,000 | -83,467,000 |
| Dec 2023 | 0 | -66,230,331 | -63,779,116 | 191,219,398 | 51,450,076 | 139,769,322 | -53,812,253 |
| Dec 2022 | 0 | -39,391,091 | -40,370,040 | 175,697,097 | 41,925,630 | 133,771,467 | -36,008,171 |
TTM Snapshot
Revenues TTM
$13,730,000
NetIncome TTM
$-192,886,000
OpCashFlow TTM
—
Assets (Latest)
$410,164,000
Forward EPS
$-0.08
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CDNA | CareDx, Inc. | $3.22B | $62.21 | — |
| VCYT | VERACYTE, INC. | $3.51B | $43.60 | — |
| NHC | NATIONAL HEALTHCARE CORP | $3.53B | $225.17 | — |
| BLLN | BillionToOne, Inc. | $4.07B | $95.41 | — |
| AVAH | Aveanna Healthcare Holdings, Inc. | $2.67B | $12.24 | — |
News headlines (Yahoo Finance, 1h cache)
Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event
2026-10-08 01:14 · Yahoo
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
2026-10-05 12:00 · Yahoo
Celcuity (CELC) Dropped, So What Is Behind Its Latest Move?
2026-10-03 01:10 · Yahoo
Celcuity Appoints David Gryska To Its Board Of Directors
2026-10-02 12:00 · Yahoo
Why Celcuity Stock Was a Winner on Wednesday
2026-09-30 21:41 · Yahoo
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
2026-09-30 12:00 · Yahoo
Is Celcuity (CELC) Stock a Buy?
2026-09-28 04:59 · Yahoo
Celcuity To Participate in Upcoming Investor Conferences
2026-09-01 12:30 · Yahoo
Celcuity (CELC): Landmark Approval Collides With A Costly Launch
2026-08-27 20:27 · Yahoo
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
2026-08-26 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.